Putting rare-cell access into practice
At QTAS, we work with leading clinics, labs, and scientific institutions to validate our quantum sensing technology on real clinical questions. This work already extends beyond liquid biopsy, across organs, sample types, and diseases.
Neuro-oncology
- Medulloblastoma
- Atypical teratoid/rhabdoid tumor (ATRT)
- Ependymoma
- Astrocytoma
- Germinoma / CNS germ cell tumor
- Leptomeningeal metastasis
- Glioblastoma
Cardiovascular diseases
- Acute myocardial infarction / unstable angina
- Primonary arterial hypertension (PAH)
- Vascular rare disease
From Rare Tumor Cells in Cerebrospinal Fluid to Molecular Insight
Can the QTAS CSF platform detect and recover tumor cells from CSF while preserving material of sufficient quality for downstream whole-genome DNA sequencing, with potential extension to RNA-based and proteomic analyses?
Discover the project
A Broader View of Circulating Tumor Cells in Liver Cancer
Can the Qtas qMRI platform accurately and reproducibly detect defined numbers of cells from EpCAM-high and EpCAM-low HCC cell lines in healthy-donor whole blood, and how does its analytical performance compare with established CTC detection and enumeration workflows?
Discover the project
Measuring Cancer Metabolism at the Single-Cell Level
Can diamond quantum-sensor-enabled magnetic resonance spectroscopy detect the conversion of hyperpolarized [1−13C]pyruvate into [1−13C]lactate within a measurement volume containing an individual cancer cell, above cell-free background, while preserving the cell’s structural integrity and viability?
Discover the project
Behind every project, a new paradigm for medicine
Our validation projects show how quantum sensing-based microscopy can move from breakthrough physics into real biological and clinical workflows.
